Welcome

Enabling drug release from medical devices

PolyActiva Pty Ltd uses a unique drug-polymer conjugate technology to enable site specific drug delivery from medical device components, such as implants, films, or fibers.

**PRESS RELEASE:  November 2020 – PolyActiva Pty Ltd, a clinical-stage Australian ophthalmology biopharmaceutical company, announced it has successfully completed its Phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant....read more…

Our Company

PolyActiva's drug-polymer conjugate technology enables site specific drug delivery from medical devices.

Videos

See how the technology works

Products

The PolyActiva product portfolio is composed of market validated products at different stages of development and with different risk / reward profiles.

Glaucoma Program

Treatment of Glaucoma:
High Dose Loadings & Complete Bioerosion

Endophthalmitis Program

Preventive & Treatment Implants:
Sustained Drug Release & Fully Biodegradable

Anti-Inflammatory Program

Intra-articular Injectable Gel & Ocular Implants:
Delivery of NSAIDs

Technology

PolyActiva has developed a platform technology that enables the slow release, site-specific drug delivery directly to the site of action.

Platform

Next generation in drug delivery

Patents

Innovation & Technology designed by PolyActiva

Pipeline

Therapeutic products for ocular diseases and other applications

Media

Contact Us